ImmunityBio (IBRX) said Thursday that the UK's Medicines and Healthcare Products Regulatory Agency accepted its marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin to treat certain patients with non-muscle invasive bladder cancer.
The application covers patients who do not respond to bacillus Calmette-Guerin and are with carcinoma in situ with or without papillary tumors, the company said.
Shares of the company were up 2.8% in recent trading.
Price: 3.33, Change: +0.09, Percent Change: +2.81
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。